Saturday, October 31, 2026

GBP/EUR Bullish Momentum: 0.89% Up In The Last 5 Sessions

ViaNews Editorial Team

February 15, 2023

GBP/EUR Bullish Momentum: 0.89% Up In The Last 5 Sessions

(VIANEWS) - GBP/EUR (GBPEUR) has been up by 0.89% for the last 5 sessions. At 22:06 EST on Tuesday, 14 February, GBP/EUR (GBPEUR) is $1.13.

GBP/EUR's yearly highs and lows, it's 4.781% up from its 52-week low and 7.04% down from its 52-week high.

Volatility

GBP/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.17%, a negative 0.01%, and a positive 0.32%, respectively.

GBP/EUR's highest amplitude of average volatility was 0.17% (last week), 0.36% (last month), and 0.32% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, GBP/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd near-term focus on the downside towards a retest of the 1.05/1.06 range – scotiabank. According to FXStreet on Monday, 13 February, "Economists at Scotiabank expect the EUR/USD to head lower towards the 1.05/06 region."
  • Eur/usd price analysis: sellers attack 1.0660 key support at monthly low. According to FXStreet on Monday, 13 February, "Following that, a two-month-old ascending resistance line near 1.0800 becomes crucial for the EUR/USD buyers.", "Hence, the quote is all set to conquer the immediate 1.0660 support, which in turn pens the south-run towards the 50% and 61.8% Fibonacci retracement level of the EUR/USD run-up from November 2022 to February 2023, respectively near 1.0630 and 1.0530."
  • Eur/usd forex signal: double bottom slowly forms - 13 February 2023. According to DailyForex on Monday, 13 February, "The EUR/USD continued pulling back as the US dollar index (DXY) strength gained steam. ", "Meanwhile, from Europe, the EUR/USD pair will react to the upcoming statement by Christine Lagarde of the European Central Bank (ECB) on Wednesday. "
  • Eur/usd could test the 1.0500 support on a strong US CPI read – ING. According to FXStreet on Monday, 13 February, "Economists at ING expect the EUR/USD to test 1.05 support on a strong US Consumer Price Index (CPI) report.", "Our medium-term view is still one of EUR/USD appreciation over the course of 2023, but we don't see clear drivers for a EUR/USD rebound this week, especially from the eurozone side."
  • Eur/usd to rise to 1.10 by Q2 – deutsche bank. According to FXStreet on Monday, 13 February, "Economists at Deutsche Bank expect the EUR/USD and GBP/USD pairs to climb towards 1.10 and 1.25 by Q2, respectively.", "There is scope for the EUR/USD to catch-up to favourable energy and monetary policy developments and reach 1.10 by Q2."

More news about GBP/EUR (GBPEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com